Merck to buy Pandion in $1.8 billion cash deal

Thursday, 25. February 2021 12:57

Merck & Co. Inc. announced on Thursday it will acquire biotechnology company Pandion Therapeutics Inc. for $60 per share in cash, or an approximate total equity value of $1.85 billion. The transaction is expected to close in the first half of 2021.

"This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics," said Merck Research Laboratories President Dr. Dean Li. "Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases."

Related Links: Merck KGaA
Breaking the News / DJ